Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.45 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344926 | 0.90 | DHODH (0.53) | DHODHKDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL27592569 | 0.89 | CA12 (0.53) | DHODHKDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL275086 | 0.88 | DHODH (0.48) | DHODHKDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL345007 | 0.87 | DHODH (0.54) | DHODHKDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL273388 | 0.87 | AKR1B1 (0.54) | DHODHKDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL343997 | 0.86 | DHODH (0.56) | DHODHMAPK8 | |
| SCHEMBL272907 | 0.85 | DHODH (0.47) | DHODHKDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL344375 | 0.85 | DHODH (0.55) | DHODH | |
| SCHEMBL345277 | 0.85 | DHODH (0.55) | DHODH | |
| SCHEMBL345159 | 0.84 | PTPN1 (0.60) | DHODHKDM4EALDH1A1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714238-B2 | Therapeutic agents for ocular hypertension | ALLERGAN, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160340347-A9 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2016-11-24 | — | — | US | disclosed |
| US-20150175586-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-8633220-B2 | Therapeutic agents for ocular hypertension | ALLERGAN, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120015978-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012003145-A2 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175586-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | PTGIR, NHERF1, PTGS1 | DHODH 1113/4885KDM4E 2429/4885ALDH1A1 753/4885 |
| US-20160340347-A9 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | PTGIR, NHERF1, PTGS1 | DHODH 1113/4885KDM4E 2429/4885ALDH1A1 753/4885 |
| US-20120015978-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | PTGIR, NHERF1, PTGS1 | DHODH 1113/4885KDM4E 2429/4885ALDH1A1 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.